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Abstract
Background-The potential of hyperechogenic fetal bowel to act as a hallmark for prenatal cystic fibrosis screening in the general population is controversial. Methods-Our goal was to evaluate the incidence of cystic fibrosis in 209 fetuses with hyperechogenic bowel diagnosed at routine ultrasonography and with no family history of cystic fibrosis. The diagnosis of cystic fibrosis was based on prenatal screening for the eight mutations most frequently observed in France (AF508, A1507, 1717-1G-A, G542X, G551D, R553X, W1282X, N1303K) and at postnatal follow up. Results-The overall incidence of cystic fibrosis was 71209 (3.3%) which is 84 times the estimated risk of CF in the general population (1/2500). Of these seven cases, six were diagnosed prenatally based on DNA analysis (AF508/AF508, n=5; AF508/ G542X, n=I). One case in which only one mutation had been recognised was diagnosed clinically after birth (AF508/ unidentified mutation). Of the seven cases, none was diagnosed at [16] [17] [18] [19] weeks, four at 16-24 weeks, and three after this. The incidence of heterozygous fetuses (15I 209, 7%) was not significantly higher than the 5% expected in the general population. The mutations involved in these heterozygous cases were AF508 (n=13), G542X (n=l), and G551D (n=I).
Conclusions-Screening for cystic fibrosis
should be offered to families in which fetal hyperechogenic bowel is diagnosed at routine ultrasonography. This underlines the need to review genetic counselling in this situation where the fetus is the index case for a genetic disease.
(3Med Genet 1998;35:657-660) Keywords: cystic fibrosis; prenatal diagnosis; ultrasound; hyperechogenic fetal bowel Hyperechogenic fetal bowel is recognised at routine ultrasound in about 0.6% of pregnancies" and is associated with a variety of fetal abnormalities."' Hyperechogenic fetal bowel is considered to be suggestive of cystic fibrosis (CF), but this remains controversial because of the lack of extensive screening for CF mutations' 10 1115 in large populations.
Our goal was to evaluate the incidence of CF in fetuses with hyperechogenic fetal bowel in order to establish the usefulness of genetic testing for cystic fibrosis transmembrane conductance regulator (CFTR) CF=cystic fibrosis; x/x=no CFTR mutation detected; CFTR=CF transmembrane regulator; TOP=termination of pregnancy; IUD=intrauterine death; CMV=cytomegalovirus infection. *Detail of screening strategy in unaffected fetuses: fetus not screened, father x/x, mother x/x (n=78); fetus x/x, parents not studied (n=75); fetus x/x, father x/x, mother x/x (n=31); fetus x/x, father AF508/x, mother x/x (n=1); fetus x/x, father x/x, mother AF508/x (n=3).
specific oligonucleotides) or enzymatic digestion and PAGE using standard procedures. Denaturing gradient gel electrophoresis (DGGE) was used to screen for other cystic fibrosis mutations, in particular when a heterozygous fetus was diagnosed. '9 All neonates were examined by a paediatrician at birth, at 1 month, and at 3 months. All heterozygous babies were screened at birth for cystic fibrosis by immunoreactive trypsin assay and a sweat test was performed at 3 months.
Results
Of the 214 Six fetuses were homozygous for CFTR mutations (five AF508/AF508, one compound heterozygous AF508/G542X). Of these, there were three terminations of pregnancy (TOP), one intrauterine death (IUD) related to maternal eclampsia, and two live births.
Fifteen fetuses were found to be heterozygous for one of the CFTR mutations tested: 13 AF508, one G542X, and one G551D. At least 15 of the more common cystic fibrosis mutations in France were screened for in these cases and none was identified. In these 15 cases, there were one TOP (intrauterine ascites diagnosed at sonographic follow up), three IUD, and 11 live births. Of the latter infants, three had bowel atresia without CF (normal sweat test), seven were symptom free and had a normal sweat test, and one had CF (meconium ileus and abnormal sweat test). In the latter case, two other sequence variations in the CFTR gene were recognised postnatally based on DGGE, but it was impossible to distinguish between polymorphism and CF related mutations.
In summary, out of 209 cases of hyperechogenic fetal bowel, 155 cases (72%) had a normal outcome and CF was diagnosed in seven cases (3.3%), none before 20 weeks, four during the period 20-24 weeks, and three after. Fifteen fetuses (7%) were heterozygous, a frequency not statistically different from that in the general population (5%).
Discussion
Until recently, prenatal diagnosis of genetic disorders was based on the identification of an increased genetic risk calculated on the basis of pedigree analysis. However, this strategy cannot prenatally identify new cases of CF where there is no family history.
Programmes have been designed to identify couples at risk based on parental screening for the most frequent mutations of the CFTR gene.20-24 However, their potential clinical value should be weighed against their cost and the ethical limitations inherent in population genetic screening. In countries in which routine obstetrical ultrasound is implemented, fetal morphological markers suggestive of a genetic disorder can be diagnosed unexpectedly in a low risk pregnancy, such as hyperechogenic fetal bowel. Many clinical problems are raised by this new approach to genetic diagnosis, in which the index case is not yet born.
Indeed, the association between hyperechogenic bowel and CF remained questionable in early reports5 1014 15 25 owing to the lack of extensive DNA screening in large patient populations and to the absence of adequate postnatal follow up.
Our results show that in the clinical setting in which the study was conducted, the incidence of CF was significantly higher in fetuses with hyperechogenic bowel than in the general population, in spite of the absence of any family history. Therefore our data can be used to evaluate the cost effectiveness of CFTR mutation screening in hyperechogenic fetal bowel, since one CF case was diagnosed prenatally per 35 fetuses tested. Ultrasound screening resulted in an acceptable detection rate (6/7). None of the children with no CFTR mutations identified prenatally developed clinical symptoms of CF postnatally. However, we are aware that the generalisation of our results should take into account the incidence of CF in the population screened and the variation in CF mutations according to ethnic background.
The major drawback of CF screening in fetuses with hyperechogenic bowel is in generating parental anxiety, especially when the fetus is found to be heterozygous for a CFTR mutation. In this situation, it is difficult to evaluate accurately the risk of misdiagnosing a rare mutation in the other apparently normal chromosome. Although not observed in this series, CF resulting from two rare mutations cannot be firmly excluded. As previously described,1' it is very important to specify the high rate of adverse pregnancy outcomes, which may approach 20-25%, as a result of CF but also congenital anomalies, chromosomal abnormalities, congenital infections, and intrauterine fetal death (probably secondary to placental haemorrhage).
In conclusion, we believe that CF screening based on ultrasound detection of hyperechogenic bowel is effective, especially in populations where CF is frequently observed. However, we are aware that this approach has intrinsic limitations because fetal sonography is implemented relatively late in gestation, and because the definition of bowel hyperechogenicity is somewhat subjective. 12 However, the prenatal identification of fetal hyperechogenic bowel is now a matter of fact in clinical practice, and our results provide an objective basis for review of genetic counselling in this novel situation of the fetus being the index case for a genetic disease. However, a prospective study needs to be undertaken in order to estimate CF frequency among fetuses without echogenic bowel and the sensitivity of ultrasound evaluation as a tool for CF screening.
